cancers-logo

Journal Browser

Journal Browser

Decoding the Tumor Microenvironment: Immune Cell–Tumor Interplay in Breast Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".

Deadline for manuscript submissions: 31 July 2026 | Viewed by 1625

Special Issue Editors


E-Mail Website
Guest Editor
Department of Hematology/Oncology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA
Interests: breast cancer

E-Mail Website
Guest Editor
Mayo Clinic Cancer Center, Rochester, MN 55905, USA
Interests: breast cancer

Special Issue Information

Dear Colleagues,

The Special Issue, entitled "Decoding the Tumor Microenvironment: Immune Cell–Tumor Interplay in Breast Cancer," delves into the complex interactions between immune cells and cancer cells that shape breast cancer development, progression, metastasis, and therapeutic responses or resistance. We highlight recent breakthroughs in understanding the breast tumor immune microenvironment, focusing on the dynamic roles of T cells, macrophages, and dendritic cells. This Issue also features advances in single-cell and spatial transcriptomics, technologies that are revolutionizing the profiling and targeting of the tumor microenvironment. Additionally, we spotlight innovative artificial intelligence-based approaches for assessing the microenvironment’s prognostic and predictive potential. Collectively, these insights are driving the development of personalized immunotherapeutic strategies for breast cancer patients.

We look forward to receiving your contributions.

Dr. Abirami Sivapiragasam
Dr. Roberto A. Leon Ferre
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • tumor microenvironment
  • breast cancer
  • immune cell–tumor interaction
  • immunotherapy
  • T cells
  • macrophages
  • dendritic cells
  • single-cell transcriptomics
  • spatial transcriptomics
  • artificial intelligence
  • prognostic biomarkers
  • predictive biomarkers
  • personalized therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

16 pages, 465 KB  
Review
The Molecular Landscape and Utility of Multiomic Analyses in Triple-Negative Breast Cancer: Further Subtyping and Exploring Novel Biomarkers and Therapeutic Targets
by Conan Juan and Yan Peng
Cancers 2025, 17(24), 4003; https://doi.org/10.3390/cancers17244003 - 16 Dec 2025
Cited by 1 | Viewed by 1345
Abstract
Triple-negative breast cancer (TNBC) has the poorest prognosis among all breast cancer subtypes, largely due to the lack of targeted therapies and its resistance to both chemotherapy and immunotherapy. A deeper understanding of TNBC biology is therefore critical for identifying therapeutic targets. Molecular [...] Read more.
Triple-negative breast cancer (TNBC) has the poorest prognosis among all breast cancer subtypes, largely due to the lack of targeted therapies and its resistance to both chemotherapy and immunotherapy. A deeper understanding of TNBC biology is therefore critical for identifying therapeutic targets. Molecular subtyping of TNBC, first introduced over a decade ago, has significantly advanced our knowledge of the disease’s biology. However, tumor heterogeneity remains a major factor contributing to poor clinical outcomes and treatment resistance. The integration of multiomic technologies, including genomic, transcriptomic, proteomic, and metabolomic analyses, offers a powerful approach to further dissect tumor heterogeneity and accelerate the discovery of new biomarkers and therapeutic targets. This review aims to highlight the potential utility and evolving role of multiomics (-omics) in improving our understanding of TNBC biology—particularly tumor heterogeneity—ultimately facilitating the development of novel therapies and actionable strategies to treat the disease. Full article
Show Figures

Figure 1

Back to TopTop